{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T10:22:25Z","timestamp":1781259745025,"version":"3.54.1"},"reference-count":44,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To estimate the real\u2010world risk of cardiovascular events among patients with migraine treated with erenumab and other migraine preventive medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Migraine preventive treatment with calcitonin gene\u2010related peptide (CGRP) pathway inhibitors, such as erenumab and others, may theoretically result in cardiovascular effects due to a lack of compensatory vasodilation with CGRP pathway inhibition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective observational cohort study, we estimated the unadjusted cumulative risk (CR) of new\u2010onset hypertension, acute myocardial infarction (MI), or stroke among patients with migraine newly treated with erenumab, other anti\u2010CGRP pathway monoclonal antibodies (mAbs), standard oral preventive medications, and onabotulinumtoxinA using data from the MarketScan\u00ae Commercial and Medicare Supplemental medical claims database. Comparative analyses to assess the relative risk (RR) of vascular events were gated on the comparability of treatment groups with respect to baseline demographics and clinical characteristics. Potential bias due to unmeasured confounding was evaluated via negative control outcome (NCO) analyses. Confounding based on measured covariates and differential informative censoring were addressed with inverse probability weights.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 108,019 new users of migraine preventive medications were included. Unadjusted CR (95% confidence interval [CI]) of hypertension at 12\u2009months of treatment was: erenumab, 9.34% (8.79\u20139.89%); other anti\u2010CGRP pathway mAbs, 9.42% (8.92\u20139.92%); standard oral preventive medications, 9.09% (8.77\u20139.41%); and onabotulinumtoxinA, 9.10% (8.39\u20139.81%). NCO analyses identified minimal concerns related to unmeasured confounding in erenumab versus other mAbs and erenumab versus onabotulinumtoxinA comparisons. Adjusted RRs (95% CIs) of acute MI and stroke, respectively, at 36\u2009months of treatment were 1.02 (0.45\u20131.59) and 0.90 (0.56\u20131.25) for erenumab versus other mAbs and 0.87 (0.19\u20131.55) and 0.97 (0.42\u20131.52) for erenumab versus onabotulinumtoxinA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this analysis of the MarketScan medical claims database, we found no difference in the risk of vascular events in patients treated with erenumab versus other anti\u2010CGRP pathway mAbs or onabotulinumtoxinA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14912","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T22:23:38Z","timestamp":1741386218000},"page":"919-932","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database\u2010based observational cohort study"],"prefix":"10.1111","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9486-6790","authenticated-orcid":false,"given":"David W.","family":"Dodick","sequence":"first","affiliation":[{"name":"Mayo Clinic  Scottsdale Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart J.","family":"Tepper","sequence":"additional","affiliation":[{"name":"New England Institute for Neurology and Headache  Stamford Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ailani","sequence":"additional","affiliation":[{"name":"Department of Neurology MedStar Georgetown University Hospital  Washington District of Columbia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ani C.","family":"Khodavirdi","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Pannacciulli","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Fu","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shia T.","family":"Kent","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karminder","family":"Gill","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Urman","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam S.","family":"Oh","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","journal-title":"Lancet"},{"key":"e_1_2_12_3_1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1468-2982.2007.01288.x","article-title":"The global burden of headache: a documentation of headache prevalence and disability worldwide","volume":"27","author":"Stovner L","year":"2007","journal-title":"Cephalalgia"},{"key":"e_1_2_12_4_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b3914","article-title":"Migraine and cardiovascular disease: systematic review and meta\u2010analysis","volume":"339","author":"Sch\u00fcrks M","year":"2009","journal-title":"BMJ"},{"key":"e_1_2_12_5_1","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1212\/WNL.0b013e3181a71220","article-title":"Migraine and cardiovascular disease: possible mechanisms of interaction","volume":"72","author":"Bigal ME","year":"2009","journal-title":"Neurology"},{"key":"e_1_2_12_6_1","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1212\/WNL.0b013e3181d0cc8b","article-title":"Migraine and cardiovascular disease: a population\u2010based study","volume":"74","author":"Bigal ME","year":"2010","journal-title":"Neurology"},{"key":"e_1_2_12_7_1","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.amjmed.2009.12.021","article-title":"Migraine headache and ischemic stroke risk: an updated meta\u2010analysis","volume":"123","author":"Spector JT","year":"2010","journal-title":"Am J Med"},{"key":"e_1_2_12_8_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020498","article-title":"Migraine and the risk of cardiovascular and cerebrovascular events: a meta\u2010analysis of 16 cohort studies including 1 152 407 subjects","volume":"8","author":"Mahmoud AN","year":"2018","journal-title":"BMJ Open"},{"key":"e_1_2_12_9_1","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/jnnp-2018-318254","article-title":"Migraine and risk of stroke","volume":"91","author":"\u00d8ie LR","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1046\/j.1468-2982.2002.00310.x","article-title":"CGRP may play a causative role in migraine","volume":"22","author":"Lassen LH","year":"2002","journal-title":"Cephalalgia"},{"key":"e_1_2_12_11_1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrneurol.2010.127","article-title":"CGRP and its receptors provide new insights into migraine pathophysiology","volume":"6","author":"Ho TW","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"e_1_2_12_12_1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s10194-017-0807-1","article-title":"Blocking CGRP in migraine patients: a review of pros and cons","volume":"18","author":"Deen M","year":"2017","journal-title":"J Headache Pain"},{"key":"e_1_2_12_13_1","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of erenumab for episodic migraine","volume":"377","author":"Goadsby PJ","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/head.13379","article-title":"History and review of anti\u2010calcitonin gene\u2010related peptide (CGRP) therapies: from translational research to treatment","volume":"58","author":"Tepper SJ","year":"2018","journal-title":"Headache"},{"key":"e_1_2_12_15_1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.yrtph.2019.05.013","article-title":"Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine","volume":"106","author":"Bussiere JL","year":"2019","journal-title":"Regul Toxicol Pharmacol"},{"key":"e_1_2_12_16_1","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1212\/WNL.0000000000008743","article-title":"Vascular safety of erenumab for migraine prevention","volume":"94","author":"Kudrow D","year":"2020","journal-title":"Neurology"},{"key":"e_1_2_12_17_1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/0333102418776017","article-title":"Phase 1, randomized, parallel\u2010group, double\u2010blind, placebo\u2010controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers","volume":"39","author":"Hoon J","year":"2019","journal-title":"Cephalalgia"},{"key":"e_1_2_12_18_1","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/cpt.799","article-title":"Phase I, randomized, double\u2010blind, placebo\u2010controlled, single\u2010dose, and multiple\u2010dose studies of erenumab in healthy subjects and patients with migraine","volume":"103","author":"Hoon J","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_12_19_1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/head.14051","article-title":"Hypertension: a new safety risk for patients treated with erenumab","volume":"61","author":"Saely S","year":"2021","journal-title":"Headache"},{"key":"e_1_2_12_20_1","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1111\/head.14208","article-title":"Risk of hypertension in erenumab\u2010treated patients with migraine: analyses of clinical trial and postmarketing data","volume":"61","author":"Dodick DW","year":"2021","journal-title":"Headache"},{"key":"e_1_2_12_21_1","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/1475-6773.12279","article-title":"Control outcomes and exposures for improving internal validity of nonrandomized studies","volume":"50","author":"Dusetzina SB","year":"2015","journal-title":"Health Serv Res"},{"key":"e_1_2_12_22_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253580","article-title":"Acute myocardial infarction: development and application of an ICD\u201010\u2010CM\u2010based algorithm to a large U.S. healthcare claims\u2010based database","volume":"16","author":"Saunders\u2010Hastings P","year":"2021","journal-title":"PLoS One"},{"key":"e_1_2_12_23_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135834","article-title":"Validity of diagnostic codes for acute stroke in administrative databases: a systematic review","volume":"10","author":"McCormick N","year":"2015","journal-title":"PLoS One"},{"key":"e_1_2_12_24_1","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models","volume":"163","author":"Brookhart MA","year":"2006","journal-title":"Am J Epidemiol"},{"key":"e_1_2_12_25_1","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity\u2010score matched samples","volume":"28","author":"Austin PC","year":"2009","journal-title":"Stat Med"},{"key":"e_1_2_12_26_1","unstructured":"BrookhartM BreskinA EledathB.CausalRisk: tools for estimating and plotting cumulative risk functions. R package version 0.39.03.2023."},{"key":"e_1_2_12_27_1","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: the randomized, double\u2010blind, placebo\u2010controlled REGAIN study","volume":"91","author":"Detke HC","year":"2018","journal-title":"Neurology"},{"key":"e_1_2_12_28_1","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the preventive treatment of chronic migraine","volume":"377","author":"Silberstein SD","year":"2017","journal-title":"N Engl J Med"},{"key":"e_1_2_12_29_1","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/0333102420912726","article-title":"Long\u2010term safety and efficacy of erenumab in patients with chronic migraine: results from a 52\u2010week, open\u2010label extension study","volume":"40","author":"Tepper SJ","year":"2020","journal-title":"Cephalalgia"},{"key":"e_1_2_12_30_1","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE\u20102","volume":"94","author":"Lipton RB","year":"2020","journal-title":"Neurology"},{"key":"e_1_2_12_31_1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1204734","article-title":"The vascular role of CGRP: a systematic review of human studies","volume":"14","author":"Al\u2010Karagholi MA","year":"2023","journal-title":"Front Neurol"},{"key":"e_1_2_12_32_1","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-019-0979-y","article-title":"CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?","volume":"20","author":"Favoni V","year":"2019","journal-title":"J Headache Pain"},{"key":"e_1_2_12_33_1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12883-021-02123-w","article-title":"Long\u2010term safety and tolerability of eptinezumab in patients with chronic migraine: a 2\u2010year, open\u2010label, phase 3 trial","volume":"21","author":"Kudrow D","year":"2021","journal-title":"BMC Neurol"},{"key":"e_1_2_12_34_1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s10194-022-01458-0","article-title":"Galcanezumab in episodic migraine: the phase 3, randomized, double\u2010blind, placebo\u2010controlled PERSIST study","volume":"23","author":"Hu B","year":"2022","journal-title":"J Headache Pain"},{"key":"e_1_2_12_35_1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s10194-023-01585-2","article-title":"Effectiveness and safety of anti\u2010CGRP monoclonal antibodies in patients over 65\u2009years: a real\u2010life multicentre analysis of 162 patients","volume":"24","author":"Mu\u00f1oz\u2010Vendrell A","year":"2023","journal-title":"J Headache Pain"},{"key":"e_1_2_12_36_1","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1111\/head.13956","article-title":"Safety and tolerability of 3 CGRP monoclonal antibodies in practice: a retrospective cohort study","volume":"60","author":"Alex A","year":"2020","journal-title":"Headache"},{"key":"e_1_2_12_37_1","article-title":"Blood pressure in patients with migraine treated with monoclonal anti\u2010CGRP (receptor) antibodies: a prospective follow\u2010up study","volume":"99","author":"Vries Lentsch S","year":"2022","journal-title":"Neurology"},{"key":"e_1_2_12_38_1","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1111\/j.1365-2222.2011.03822.x","article-title":"The neuropeptide calcitonin gene\u2010related peptide affects allergic airway inflammation by modulating dendritic cell function","volume":"41","author":"Rochlitzer S","year":"2011","journal-title":"Clin Exp Allergy"},{"key":"e_1_2_12_39_1","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s11606-011-1937-9","article-title":"Blood pressure monitoring technique impacts hypertension treatment","volume":"27","author":"Ray GM","year":"2012","journal-title":"J Gen Intern Med"},{"key":"e_1_2_12_40_1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jacc.2018.10.069","article-title":"Blood pressure assessment in adults in clinical practice and clinic\u2010based research: JACC scientific expert panel","volume":"73","author":"Muntner P","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_12_41_1","doi-asserted-by":"crossref","DOI":"10.1177\/1753944720931637","article-title":"Current status of white coat hypertension: where are we?","volume":"14","author":"Nuredini G","year":"2020","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"e_1_2_12_42_1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/eurpub\/ckab219","article-title":"Prevalent migraine as a predictor of incident hypertension","volume":"32","author":"Entonen AH","year":"2022","journal-title":"Eur J Pub Health"},{"key":"e_1_2_12_43_1","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/head.13316","article-title":"A randomized, double\u2010blind, placebo\u2010controlled study to evaluate the effect of Erenumab on exercise time during a treadmill test in patients with stable angina","volume":"58","author":"Depre C","year":"2018","journal-title":"Headache"},{"key":"e_1_2_12_44_1","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/head.14485","article-title":"Evaluation of vascular risk in patients with migraine with and without aura treated with erenumab: post hoc analysis of pooled long\u2010term clinical trial data","volume":"63","author":"Kudrow D","year":"2023","journal-title":"Headache"},{"key":"e_1_2_12_45_1","first-page":"1","article-title":"Migraines and CGRP monoclonal antibodies: a review of cardiovascular side effects and safety profile","volume":"7","author":"Boldig K","year":"2020","journal-title":"Int J Neurol Neurother"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14912","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:44:05Z","timestamp":1762076645000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1111\/head.14912"],"URL":"https:\/\/doi.org\/10.1111\/head.14912","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"2024-06-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}